Close Menu


Persephone Biosciences has launched a prospective, longitudinal study to evaluate 4,000 patients' gut microbiomes and link them with cancer treatment response.

The firm will collect stool and blood samples from 4,000 cancer patients and determine whether their microbiome composition affects their response to therapy.

Researchers used whole-genome shotgun metagenomic sequencing to home in on specific bacteria associated with patients' response to immune checkpoint inhibitor treatment.

The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.

Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.

The collaboration will test the effects of using human microbiome-derived bacteria alongside immune checkpoint inhibitor nivolumab to treat advanced metastatic cancers.

Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.